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ABSTRACT
Aim: To determine the effect of gender difference in the antidepressant effect of fluoxetine (FLX) in mice in tail suspension test (TST).
Methods: Swiss albino mice of either sex were used and the depression-like behavior was measured by TST.
Results: The present study showed that there was a significant difference in the immobility period of male mice and female mice in TST. However, the 
antidepressant effect of FLX differs significantly in male mice and female mice in TST.
Conclusion: It has been concluded that the antidepressant effect of FLX in TST was affected by the gender difference as suggested by the results of 
the present study.
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INTRODUCTION
Depression is a multifaceted heterogeneous disorder with the 
symptoms characterized at psychological, behavioral, and physiological 
levels [1]. Various symptoms of depression include anhedonia, loss 
of energy, low self-esteem, disturbed sleep or appetite, low energy, 
poor concentration, and suicidal intentions [2-4]. Alteration in the 
levels of the neurotransmitters has been found to be responsible for 
the pathogenesis of depression, but recently, it is suggested that the 
depression which is considered as a disorder that arises due to the 
imbalance in the levels of the neurotransmitters in the brain also 
arises due to the alterations in the activities of the various enzymes 
that catalyze the synthesis and metabolism of the neurotransmitters 
implicated in the pathogenesis of depression [5]. Serotonin 
(5-hydroxytryptamine [5-HT]) is a neurotransmitter that regulates 
mood and behavior [6], and its deficiency and reduced transmission 
contribute to depression [7]. Therefore, the drugs that correct the 
deficiency of 5-HT exerts antidepressant effect. Selective serotonin 
reuptake inhibitors (SSRIs) inhibit the reuptake of 5-HT into presynaptic 
neurons; increased its concentration in the synaptic cleft and are thus 
effective in the treatment of mood disorders, e.g., depression [8].
In rodents, the depression-like behavioral alteration can be measured by 
using tail suspension test (TST) [9,19]. In TST, animal initially shows some 
escape-oriented behavior but develops immobility after some escape 
attempts [10,11]. Immobility developed by the animals is the behavioral 
despair and represents symptom of depression [19,12]. Immobility 
thus reflects a specific state of mammalian defense repertoire known as 
arrested flight correlated with the psychological construct of entrapment 
in clinical depression [13-15]. This behavioral despair is similar to human 
depression and represents the psychomotor retardation in depressed 
patients [10,16]. Therefore, the reduction in the total immobility period 
indicates an antidepressant effect [17]. SSRIs are clinically proven 
antidepressants that reduce immobility period of animals in TST [9].
Sex differences have been found to influence the depression-
related behavior [18]. Women experience major depression twice 
as compared to men [19-21] and in women depressive episodes are 
more protracted and recurs more frequently than men [19,20]. The 
main reason behind this is the cyclical change in the estrogen levels 
that increases their vulnerability to mood disorders [22-24]. The 
fact is further confirmed by the findings from the studies stated that 
the plasma estrogen levels are significantly lower among depressed 
women [21]. Results from the preclinical studies reported that 
the females are less immobile than males in FST at all stages of 
estrous cycle, [30], or the immobility is less particularly only during 
proestrus phase [31]. The findings from the observational and 
clinical studies supported a neurobiological basis for the multiple 
salutary effects of estrogen on mood during periods of estrogenic 
fluctuation [33]. Therefore, if the endogenous fluctuations in estrogen 
are responsible for negative effect, stabilizing estrogen levels via 
exogenous administration would exert the positive effect [34]. 
Estrogenic substances have been shown to exert the antidepressant-
like effect in rodents in FST [27-29]. Estrogen is serotonergic agonist 
that acts via various mechanisms [32]. Furthermore, estrogen when 
administered systemically block 5-HT transporter (SERT) [26], and 
therefore, may modulate the antidepressant effects of the drugs that 
modulate the functioning of SERT. In the light of the above findings, a 
study was required to determine the effect of gender difference on the 
antidepressant effect of fluoxetine (FLX) in mice in TST.
METHODS
Animals
Swiss albino mice either sex were procured from Lala Lajpat Rai 
University of Veterinary and Animal Sciences, Hisar. All the animals 
were kept under controlled light and environmental conditions and had 
free access to food and water. Animals were allowed to acclimatize to 
laboratory conditions before the experiment. All the experiments were 
carried out between 9:00 and 16:00 hrs. The experimental protocols 
were approved by the Institutional Animal Ethics Committee, and care 
of the animals was carried out in compliance with the guidelines of the 
Committee for the Purpose of Control and Supervision of Experiments 
on Animals.
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Drugs and selection of dose
FLX was purchased from the Cadila Pharmaceuticals, Ahmedabad. The 
dose was selected according to the previous studies [35].
Assessment of depression-like behavior in mice
Tail suspension test
TST is the most commonly used behavioral test for the assessment 
of depression-like behavioral alterations in mice. Each mouse was 
individually suspended at a height of 30 cm from the floor, by adhesive 
tape placed approximately 1 cm from the tip of the tail. Each mouse was 
then observed individually for a period of 6 minutes for the assessment 
of immobility period [19].
Experimental protocol
Swiss albino mice either sex were used in the present study. The mice 
were administered with FLX (20 mg/kg, i.p.) [35], and the depression-
like behavioral alterations in both male and female mice were measured 
using TST [19].
Statistical analysis
Data were analyzed by one-way ANOVA followed by Tukey’s Post-hoc 
test. p<0.05 was considered as statistically significant.
RESULTS
Effect of gender difference of mice in TST
The effect of gender difference on the immobility period of male and 
female mice was shown in the Fig. 1. Immobility period of female mice 
was significantly greater than the male mice. There was a significant 
difference in the immobility period of FLX (20 mg/kg, i.p.) treated male 
mice and FLX (20 mg/kg, i.p.) treated female mice.
DISCUSSION
Depression is a chronic mental disease that affects more than 10% 
of population [36] and has become one of the most prevalent public 
health problems because of high rate of morbidity, recurrence, 
and mortality [37]. Depression is more common in females than 
males [38] and the women tend to have more depressive symptoms, 
during the times of large hormonal changes, suggesting that the hormonal 
changes plays a key role in the pathogenesis of depression [39,40]. In 
rodents, behavioral depression can be assessed using TST. The results 
of the present study revealed that the depression-like behavior were 
more in female mice as compared to male mice because the immobility 
period of female mice were significantly greater than the male mice in 
TST. Female rats have increased immobility in FST as compared to male 
rats as suggested by the previous studies [41]. Thus, female rodents 
show more depression-like behavior than males as suggested by the 
present study and is further confirmed by the findings of the previous 
studies reported in literature [41]. Estrous cycle in the females had 
been known to produce the phase-dependent effects on the depressive 
behavior [46,47]. This is one of the major reasons for the exclusion of 
female mice from behavioral testing because the hormonal fluctuation 
that occurs in the females during the estrous cycle; could potentially 
affect the animal behavior and complicates the data interpretation. 
Thus, sex/gender difference influence both the pathogenesis and 
evaluation of the psychiatric disorders such as depression and 
anxiety [48,49]. Depression is also mediated, by the alteration in 
hypothalamic-pituitary-adrenal axis (HPA) which is further modulated 
by the steroids of hypothalamic-pituitary-gonadal axis [25,42-45]. 
Neurotransmitters such as GABA and 5-HT that are mainly implicated 
in the pathogenesis of psychiatric disorders go through the functional 
changes along with the estrous cycle [50,51]. Estrogen contributes to the 
normal functioning of HPA axis [52-54], and the high levels of estrogen 
decrease the depressive behavior in females [31]. Furthermore, the 
estrogen therapy has been reported to exert antidepressant effects 
in perimenopausal and postmenopausal women [65]. The exact 
mechanism by which estrogen exerts antidepressant-like effect or 
reduces the depressive behavior is not known exactly but it is likely to be 
mediated by the activation of estrogen receptor beta [64]. Furthermore, 
the administration of estrogen upregulates 5-HT synthesizing enzyme, 
i.e. tryptophan hydroxylase [55,56], downregulates SERT upon short-
term treatment [57], whereas upregulates SERT following long-term 
treatment [58], decreases the expressions of 5-HT metabolizing 
enzyme, i.e., monoamine oxidase [59], and reduces the expression 
of 5-HT1A receptor in the various regions of brain [60,61]. Therefore, 
estrogen modulates both the density of 5-HT receptors and 5-HT 
turnover [62,63]. Thus, if estrogen influences 5-HT synthesizing and 
metabolizing enzyme, receptors, autoreceptors, and transporters, 
then it may also modulate the therapeutic effect of the drugs that 
influence the levels of 5-HT. To confirm this, we administered FLX 
(20 mg/kg, i.p.) to both male and female mice and the immobility 
period was determined by TST. Administration of FLX (20 mg/kg, i.p.) 
to both male and female mice significantly reduced the immobility 
period of both male and female mice as compared to their respective 
control. Also, the immobility period of FLX (20 mg/kg, i.p.) treated 
male mice was significantly less as compared to the immobility period 
of FLX (20 mg/kg, i.p.) treated female mice. Thus, there is a significant 
difference in the antidepressant effect of FLX (20 mg/kg, i.p.) in male 
and female mice. Therefore, it is suggested that the FLX (20 mg/kg, 
i.p.) produced more marked antidepressant effect in male as compared 
to female mice. However, the exact mechanism by which the FLX 
(20 mg/kg, i.p.) produced more marked antidepressant effect in male 
is not explained by the present study. This might be one of the main 
reasons why the males are more vulnerable to the adverse effects of the 
SSRIs as compared to the females.
CONCLUSION
It has been concluded that the depression-like behavioral alteration 
was more in the female mice as compared to the male mice. In the 
present study, FLX exerted greater antidepressant effect in male mice 
as compared to the female mice. Furthermore, the antidepressant 
effect of FLX has been shown to be affected by the gender difference 
in TST, and therefore, the care should be taken while selecting the sex 
of animals used for the screening of the antidepressants-like activity 
by TST. Furthermore, the present study showed that the males are 
more susceptible to FLX as compared to the females, and therefore, the 
chances of getting adverse effects in the male are more as compared to 
the females.
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